Report overview

The report presents FY18 as a landmark year for Biocon, led by U.S. approval of its Ogivri biosimilar Trastuzumab. It reports that renewable energy reached 39% of total power consumption and that the eLAJ network expanded to 21 smart clinics. The sustainability section also describes environmental conservation and community healthcare initiatives.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017-2018
Period: 1 April 2017 – 31 March 2018
Language
Pages
File size

Standards & Assurance

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Renewable energy
Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services

Report overview

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017-2018
Period: 1 April 2017 – 31 March 2018
Language
Pages
File size

Standards & Assurance

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Renewable energy
Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services

Enduring Edge Annual Report

Report overview

Document

Standards & Assurance

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.

Enduring Edge Annual Report

Report overview

Document

Standards & Assurance

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.